Health Catalyst, Inc. (NASDAQ:HCAT) Receives Consensus Rating of “Hold” from Analysts

Health Catalyst, Inc. (NASDAQ:HCAT) has earned a consensus rating of “Hold” from the eleven analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $2.45.

HCAT has been the subject of a number of research analyst reports. Citigroup lowered their price target on Health Catalyst from $2.50 to $2.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Weiss Ratings raised shares of Health Catalyst from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. Canaccord Genuity Group reiterated a “hold” rating and set a $1.80 price target (down from $3.00) on shares of Health Catalyst in a research report on Thursday, August 20th. Finally, Wells Fargo & Company decreased their price objective on shares of Health Catalyst from $1.75 to $1.50 and set an “equal weight” rating on the stock in a report on Thursday, August 13th.

Hedge Funds Weigh In On Health Catalyst

Hedge funds and other institutional investors have recently bought and sold shares of the company. Palogic Value Management L.P. purchased a new position in shares of Health Catalyst in the 2nd quarter valued at about $9,796,000. BlackRock Inc. purchased a new stake in shares of Health Catalyst during the 2nd quarter worth $3,654,000. Hsbc Holdings PLC purchased a new position in Health Catalyst in the second quarter valued at $809,000. HighMark Wealth Management LLC raised its stake in Health Catalyst by 139.0% in the fourth quarter. HighMark Wealth Management LLC now owns 741,482 shares of the company’s stock valued at $1,772,000 after buying an additional 431,200 shares in the last quarter. Finally, Visionary Wealth Advisors acquired a new stake in Health Catalyst in the second quarter valued at $27,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Health Catalyst Stock Performance

HCAT stock opened at $1.73 on Friday. The company has a debt-to-equity ratio of 1.51, a current ratio of 2.70 and a quick ratio of 2.70. The company has a market capitalization of $130.20 million, a PE ratio of -0.47 and a beta of 1.53. The firm’s 50-day moving average is $1.94 and its 200 day moving average is $1.64. Health Catalyst has a 12 month low of $0.96 and a 12 month high of $3.62.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.01. Health Catalyst had a negative return on equity of 1.83% and a negative net margin of 90.61%.The business had revenue of $70.49 million during the quarter, compared to the consensus estimate of $69.09 million. On average, research analysts anticipate that Health Catalyst will post -0.18 EPS for the current year.

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.